UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
Amendment No. 1
(Mark One)
x
ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended
August 31, 2012
or
¨
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
__________ to __________
Commission file number 000-52309
WHOLEHEALTH
PRODUCTS, INC.
(Exact name of registrant as specified in its
charter)
|
|
Nevada
|
98-048932
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
2012 Business Center Drive, Suite 115I, Irvine,
California 92612
(Address of principal executive offices)
(949) 253-4616
(Registrant’s telephone number, including area code)
|
|
Securities registered under Section 12(b) of the Act:
|
None
|
|
|
Securities registered under Section 12(g) of the Act:
|
None
|
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes
¨
No
þ
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act. Yes
¨
No
þ
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter
period that the
registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
¨
No
þ
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§ 232.405) during the precedent 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes
þ
No
¨
Indicate by check mark if disclosure of delinquent
filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form 10-K.
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of
“
l
arge
accelerated filer,”
“accelerated filer” and
“smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
þ
|
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). Yes
¨
No
þ
State the aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold,
or the average bid and asked price of such common equity, as of February 28, 2012: $19,811,087.
As of August 31, 2012, the registrant had 53,814,054 outstanding
shares.
Documents incorporated by reference: None.
EXPLANATORY
NOTE
Wholehealth
Products, Inc. is filing this Amendment No. 1 to our Form 10-K Annual Report, as filed with the U.S. Securities and Exchange Commission
on December 14, 2012, to revise Item 8.
All other items remain unchanged from the original filing.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The Annual Report on Form 10-K contains
forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on Wholehealth
Products, Inc.’s current expectations, assumptions, estimates and projections about its business and industry. Words such
as “believe,” “expect,” “intend,” “plan,” “may” and other similar expressions
identify forward-looking statements. In addition, any statements referring to expectations, projections or other characterizations
of future events or circumstances are forward-looking statements. These forward-looking statements are subject to certain risks
and uncertainties that could cause actual results to differ materially from those stated in the forward-looking statements. Investors
should further understand these forward-looking statements are based on the limited knowledge currently available to everyone concerned.
Since many assumptions herein are likely to vary from what will actually occur, investors should treat all forward-looking statements
only as illustrations based upon the assumptions and not as the operating results of Wholehealth Products, Inc. Therefore, investors
are cautioned not to place undue reliance on forward-looking statements, which relate only to beliefs, expectations or intentions
as of the date on which the statements are made. Wholehealth Products, Inc. undertakes no obligation to publicly revise these forward-looking
statements to reflect events or circumstances arising after the date hereof. Thus, investors should refer to and carefully review
information in future documents Wholehealth Products, Inc. files with the Securities and Exchange Commission.
PART I
ITEM 1. BUSINESS
Corporate History
Wholehealth Products, Inc. formerly Gulf Western
Petroleum Corporation (the Company) was incorporated on February 21, 2006 in the State of Nevada as Georgia Exploration, Inc. The
name was originally changed on March 8, 2007 and recently in July 2012 to Wholehealth Products, Inc. The Company was engaged in
the acquisition, exploration and development of oil and natural gas reserves in the United States.
General Overview
The Company today is in the business of developing,
manufacturing and marketing in vitro diagnostic (IVD) tests for over-the-counter (OTC or consumer), and point-of-care (POC or professional)
use markets. The Company currently manufactures and markets a range of diagnostic test kits for consumer use through over-the-counter
(OTC) sales, and for use by health care professionals, generally located at medical clinics, physician offices and hospitals known
as Points-of-Care (POC), in the United States. These test kits are known as in vitro diagnostic test kits or “IVD”
products.
Research and Development
Our business plan is focused on expanding in the medical field but
we do not anticipate that we will expend any significant funds on research and development.
Purchase of Significant Equipment
We do not intend to purchase any significant equipment over the
next twelve months, other than in the ordinary course of business.
Employees
We currently have three full-time and part-time
employees. We generally utilize short term contractors, consultants and professional service providers, as necessary. Our directors
and officers provide services on a month to month basis pursuant to oral arrangements, but have not signed employment or consulting
agreements with us. We do not expect any material changes in the number of employees over the next twelve month period. We may
enter formal written service agreements with our directors and officers in the future. We expect to utilize contractors and consultants
as needed to meet our staffing needs, and will continue to periodically evaluate costs and benefits of staffing our resource requirements
externally or internally. We expect that the level of success of our exploration and development initiatives will drive the timing
and level of employees that we may retain in the future.
Going Concern
Our financial statements have been prepared
assuming we will continue as a going concern. We are in our development stage and, accordingly, have several capital initiatives
but no revenues. We have raised limited financing and have incurred operating losses since our inception. These factors raise substantial
doubt about our ability to continue as a going concern, and our ability to achieve and maintain profitability and positive cash
flows are dependent on our ability to secure sufficient financing to fund the acquisition, drilling and development of profitable
oil and natural gas properties. We are actively pursuing financing options which we believe would allow us to establish and sustain
commercial production. There are no assurances that we will be able to obtain additional financing from investors or private lenders
and, if available, such financing may not be on commercial terms acceptable to us or our stockholders. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty. We intend to raise financing sufficient
to fund our capital expenditure and working capital requirements for the next twelve months principally through private placements
and possibly public offerings.
ITEM 1A. RISK FACTORS
You should carefully consider these
factors that may affect future results, together with all of the other information included in this Form 10-K/A, in evaluating
the business and the Company. The risks and uncertainties described below are those that the Company currently believes may materially
affect its business and results of operations. Additional risks and uncertainties that the Company is unaware of or that
it currently deems immaterial also may become important factors that affect its business and result of operations. The Company’s
common shares involve a high degree of risk and should be purchased only by investors who can afford a loss of their entire investment.
Prospective investors should carefully consider the following risk factors concerning the Company’s business before
making an investment.
In addition, you should carefully
consider these risks when you read “forward-looking” statements elsewhere in this Form 10-K/A. These are statements
that relate to the Company’s expectations for future events and time periods. Generally, the words “anticipate,”
“expect,” “intend,” and similar expressions identify forward-looking statements. Forward-looking
statements involve risks and uncertainties, and future events and circumstances could differ significantly from those anticipated
in the forward-looking statements.
Early Revenue Stage Company: Generation of Revenues
The Company is an early revenue stage
company and an investor cannot readily determine if the Company will become profitable. The Company is likely to continue to experience
financial difficulties during this early revenue stage and beyond. The Company may be unable to operate profitably, even if it
generates additional revenues. The Company may not obtain the necessary working capital to continue developing and marketing
its products. Furthermore, the present products may not receive sufficient interest to generate revenues or achieve profitability.
Need for Future Capital: Long-Term Viability of Company
The Company will need additional capital
to continue its operations.
There can be no assurance that the
Company will generate revenues from present operations or obtain sufficient capital on acceptable terms, if at all. Failure
to obtain such capital or generate such operating revenues would have an adverse impact on the Company’s financial position,
operations and ability to continue as a going concern. The company’s.’ operating and capital requirements during
the next fiscal year and thereafter will vary based on a number of factors, including the level of sales and marketing activities
for its services and products. There can be no assurance that additional private or public financing, including debt or equity
financing, will be available as needed or if available, on terms favorable to the Company. Additionally, any future equity financing
may be dilutive to stockholders present ownership levels and such additional equity securities may have rights, preferences, or
privileges that are senior to those of the Company’s existing common stock.
Furthermore, debt financing, if available,
may require payment of interest and potentially involve restrictive covenants that could impose limitations on the flexibility
of the Company to operate. The Company’s difficulty or failure to successfully obtain additional funding may jeopardize its
ability to continue the business and its operations.
Unpredictability of Future Revenues:
Potential Fluctuations in Operating Results
As a result of the Company’s
limited operating history; the Company is currently unable to accurately forecast its revenues. Current and future expense levels
are based largely on the Company’s marketing and development plans and estimates of future revenue. Sales and operating
results generally depend on volume and timing of orders and on the Company’s ability to
fulfill such orders, both of which
are difficult to forecast. The Company Corp. may be unable to adjust spending in a timely manner to compensate for any unexpected
revenue shortfall. Accordingly, any significant shortfall in revenues in relation to planned expenditures could have an immediate
adverse effect on the Company’s business, prospects, financial condition and results of operations. Further, as a strategic
response to changes in the competitive environment, The Company may from time to time make certain pricing, service or marketing
decisions that could have a material adverse effect on its business, prospects, financial condition and results of operations.
The Company may experience significant
fluctuations in future operating results due to a variety of factors, many of which are outside the Company’s control. Factors
that may affect operating results include: (i) ability to obtain and retain customers, (ii) attract new customers at
a steady rate and maintain customer satisfaction with products, (iii) the announcement or introduction of new services by
Wholehealth Products, Inc. or its competitors, (iv) price competition, (v) the level of use and consumer acceptance of
its products, (vi) the amount and timing of operating costs and capital expenditures relating to expansion of the business, operations
and infrastructure, (vii) governmental regulations, and (viii) general economic conditions.
Flaws and Defects in Products
Products offered by the Company may
contain undetected flaws or defects when first introduced or as new versions are released. Any inaccuracy or defects may result
in adverse product reviews and a loss or delay in market acceptance. There can be no assurance that flaws or defects will not be
found in the Company’s products. Flaws and defects, if found, could have a materially adverse effect upon the business operations
and financial condition of the Company. Marketing of any of the Company’s potential products may expose the Company
to liability claims resulting from the use of the Company’s products. These claims might be made by consumers, health care
providers, sellers of the Company’s products or others. A claim, particularly resulting from a clinical trial, or a product
recall could harm the Company’s business, results of operations, financial condition, cash flow and future prospects.
Stock Price Volatility
The market price of the Company’s
stock has fluctuated in the past and may continue to fluctuate in the future. The Company believes such fluctuations
will continue as a result of many factors, including US and World markets, financing plans, future announcements concerning the
Company, the Company’s competitors, principal customers regarding financial results or expectations, industry supply or demand
dynamics, new product introductions, governmental regulations, the commencement or results of litigation or changes in earnings
estimates by analysts. In addition, in recent years the stock market has experienced significant price and volume fluctuations
often for reasons outside the control of the particular companies. These fluctuations as well as general economic, political
and market conditions may have an adverse affect on the market price of the Company’s common stock.
Worldwide Economic Conditions
The Company’s financial performance
depends significantly on worldwide economic conditions and the related impact on levels of consumer spending, which has recently
deteriorated significantly in many countries and regions, including the U.S., and may remain depressed for the foreseeable future. Demand
for the Company’s products may be adversely affected by negative macroeconomic factors affecting consumer spending. Substantial
tightening of consumer credit, low consumer liquidity, and extreme volatility in credit and equity markets have weakened consumer
confidence and decreased consumer spending. These and other economic factors have reduced demand for the Company’s
products and harmed the Company’s business, financial condition and results of operations, and to the extent such economic
conditions continue, they could cause further harm to the Company’s business, financial condition and operations.
Dependence on Sales through Retailers and Distributors
The Company’s business that depends
significantly upon sales through retailers and distributors may be affected if the Company’s retailers and distributors are
not successful. As a result, the Company could experience reduced sales, substantial product returns or increased price protection,
any of which would negatively impact the Company’s business, financial condition and results of operations. A
significant portion of the Company’s sales are made through retailers, either directly or through distributors. If
the Company’s retailers and distributors are not successful, due to weak consumer retail demand caused by the current worldwide
economic downturn, decline in consumer confidence, or other factors, the Company could continue to experience reduced sales as
well as substantial product returns or price protection claims, which could harm the Company’s business, financial condition
and operations.
Limited Management Personnel
Under the Company’s business
plan, significant and material matters of business must be conducted and concluded in a timely fashion. The execution of
the Company’s business plan places a significant strain on the Company’s management while providing little or no immediate
compensation.
There can be no assurance that the
Company’s planned personnel, systems, procedures and controls will be adequate to support its future operations, management
will be able to hire, train, retain, motivate and manage personnel or that its management will be able to successfully identify,
manage and exploit existing and potential market opportunities. If the company is unable to manage growth effectively, the Company’s
business, prospects, financial condition, results and operations could be adversely affected.
Competition
The market in which Wholehealth Products,
Inc. competes is highly competitive, and the Company has no assurance that it will be able to compete effectively, especially against
established industry competitors with significantly greater financial resources. The Company expects it may face competition from
a few competitors with potentially greater financial resources, well-established brand names and large, pre-existing customer bases.
Dependence on Management
The Company’s performance will
be substantially dependent on the continued services and on the performance of the current senior management and other key personnel
of the Company. The Company’s performance will also depend on the Company’s ability to retain and motivate its other
officers and key employees. The Company’s inability to retain its executive officers or other key employees could have
a material adverse effect on the Company’s business, prospects, financial condition and results of operations. The
Company’s future success depends to a great extent on its ability to identify, attract, hire, train, retain and motivate
other highly skilled technical, managerial, merchandising, marketing and customer service personnel. Competition for such
personnel can be intense and there is no assurance the Company will be able to successfully attract, assimilate and retain sufficiently
qualified personnel. The failure to retain and attract the necessary technical and managerial personnel could have a material adverse
effect on the Company’s business, prospects, financial condition and results of operations.
Development of Brand Awareness
For certain market segments that the
company plans to pursue, the development of its brand awareness is essential for it to reduce its marketing expenditures over time
and realize greater benefits from marketing expenditures. If the Company’s brand-marketing efforts are unsuccessful,
growth prospects, financial condition and results of operations would be adversely affected. Wholehealth Products, inc. brand awareness
efforts have required, and will most likely continue to require additional expenses.
Intellectual Property Protection: Uncertainty of
Protection of Proprietary Rights
Wholehealth Products, Inc. currently
relies on a combination of patents, trademarks, trade secret protection, non-disclosure agreements and licensing arrangements to
establish and protect its proprietary rights. Despite efforts to safeguard and maintain the company’s proprietary rights,
there can be no assurance the Company will be successful in doing so or its competitors will not independently develop products
substantially equivalent or superior.
The Company also relies on trade secrets
and proprietary know-how, which the Company seeks to protect by confidentiality and non-disclosure agreements with its employees,
consultants, and third parties. There can be no assurance that these agreements will not be breached, that the Company will
have adequate remedies for any breach, or that certain of the company’s trade secrets and proprietary know-how will not otherwise
become known or be discovered by competitors.
Protecting or defending the Company’s
IP rights, to protect trade secrets, to determine the validity and scope of the proprietary rights of others, or to defend against
claims of infringement or invalidity may require litigation. Such litigation, whether successful or unsuccessful, could result
in substantial costs and diversions of management resources, either of which could have a materially adverse effect on the Company.’
business, prospects, financial condition, or operating results.
Availability and Coverage of Insurance
For certain risks, the Company does not maintain
insurance coverage because of cost and/or availability. Because the Company retains some portion of its insurable risks, and
in some cases self-insures completely, unforeseen or catastrophic losses in excess of insured limits could have a material adverse
effect on the Company’s financial condition and operating results.
Penny Stock Regulation
The Company’s securities sold
as part of financing provided to the Company may be subject to “penny stock rules” that impose additional sales requirements
on broker-dealers who sell such securities to persons other than established customers and accredited investors, the latter of
which are generally people with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly. For transactions
covered by these rules, the Company and/or broker-dealer must make a special suitability determination for the purchase of such
securities and have received the purchaser’s written consent to the transaction prior to the purchase. Additionally,
for any transaction involving a penny stock, unless exempt, the “penny stock rules” require the delivery, prior to
the transaction, of a disclosure schedule prescribed by the Securities and Exchange Commission relating to the penny stock market. The
broker-dealer must also disclose the commissions payable to both the broker-dealer and the registered representative and current
quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market
in penny stocks. Consequently, the “penny stock rules” may restrict the ability of broker-dealers to sell the Company’s
securities. The foregoing required penny stock restrictions will not apply to the Company’s common stock if such securities
maintain a market price of $5.00 or greater. Therefore the challenge for the Company is that the market price of the Company’s
common stock may not reach or remain at such a level.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
The Company is located in Las Vegas, but will soon relocate to Irvine
California.
ITEM 3. LEGAL PROCEEDINGS
None.
ITEM 4. MINING SAFETY DISCLOSURES
None.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Shares of the Company's common stock
are quoted and traded on the OTC Markets (www.otcmarkets.com) via the trading symbol “GWPC.”
The following table sets forth the high and
low bid prices for the Company's shares for each quarter during the two fiscal years ended August 31, 2012 and 2011. The prices
reflect inter-dealer prices, without retail mark-up, mark-down or commission and are not intended to represent actual transactions.
Date
|
|
Bid Price
|
FY 2012
|
|
HIGH
|
|
LOW
|
First Quarter
|
|
.85
|
|
.65
|
Second Quarter
|
|
.75
|
|
.35
|
Third Quarter
|
|
.55
|
|
.20
|
Fourth Quarter
|
|
.40
|
|
.02
|
FY 2011
|
|
HIGH
|
|
LOW
|
First Quarter
|
|
.85
|
|
.65
|
Second Quarter
|
|
.75
|
|
.35
|
Third Quarter
|
|
.55
|
|
.20
|
Fourth Quarter
|
|
.40
|
|
.02
|
At August 31, 2012, the market price
of the Company's common stock was .02 per share.
As of August 31, 2012, there were 53,814,054
issued and outstanding shares of common stock held by an estimated 352 holders of record.
DIVIDEND POLICY. The Company has not
paid and do not plan to pay cash dividends at this time.
ISSUER PURCHASES OF EQUITY SECURITIES.
The Company did not repurchase any of its securities during the year ended August 31, 2012.
SECURITIES AUTHORIZED FOR ISSUANCE
UNDER EQUITY COMPENSATION PLANS. The Company currently does not maintain any equity compensation plans.
ITEM 6. SELECT FINANCIAL DATA
Not applicable.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
REVENUES
Total revenue was $0 for the year ended
August 31, 2012 and 2011.
RESEARCH AND DEVELOPMENT
There were no research and development cost during the fiscal year
ended August 31, 2012 and August 31, 2011.
OPERATING EXPENSES
Total operating expenses for the fiscal year ended August 31, 2012
and August 31, 2011 were $372,000 and 12,000.
LIQUIDITY AND CAPITAL RESOURCES
As of August 31, 2012, the Company
had a deficiency in working capital of $0.
OFF-BALANCE SHEET ARRANGEMENTS
The Company has no off-balance sheet
arrangements, special purpose entities, financing partnerships or guarantees.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
Not applicable.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA
The financial statements of the Company
and supplementary data are included beginning immediately before the signature page to this report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
The Company’s upper Management,
including the Chief Executive, Chief Financial, and Chief Operating Officers, as of the end of the period covered by this Annual
Report on Form 10-K/A, have concluded our disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under
the Securities Exchange Act of 1934) were not effective as described in the act, although efforts were made to do so and to ensure
information required to be disclosed in reports we file or submit under the Exchange Act are recorded, processed, summarized and
reported within the time periods specified in SEC rules and forms. As we continue to expand, we aim to become effective in the
areas of disclosure controls and procedures in order to move the Company forward successfully.
Management, including the Chief Executive Officer/Chief
Financial Officer and Chief Operating Officer, do not expect its present disclosure controls and procedures nor its internal controls
will allow nor prevent all error or fraud. A control system, no matter how well conceived and operated, can provide
only reasonable, not absolute assurance the objectives of the control system are met. Further, the design of a control
system must reflect the fact that resource constraints and the benefits of controls must be considered relative to their costs. Due
to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance all control issues
and instances of fraud, if any, have been detected. To address the material weaknesses, management performed additional analysis
and other post-closing procedures in an effort to ensure its consolidated financial statements included in this annual report have
been prepared in accordance with generally accepted accounting principles and are as free of fraud as best as can be determined.
Accordingly, management believes the financial statements included in this report fairly present in all material respects our financial
condition, results of operations and cash flows for the periods presented.
Changes in Internal Controls
.
There were no significant changes in
our internal controls or other factors that could significantly affect these controls subsequent to the date of their evaluation.
There were no deficiencies or material weaknesses recognized as of August 31, 2012, and therefore no corrective actions were deemed
necessary. However, the design of any system of controls is based in part upon certain assumptions about the likelihood of future
events and there is no certainty that any design will succeed in achieving its stated goal under all potential future considerations,
regardless of how remote. It is management’s plan however, to work toward better assessment of any and all necessary
internal controls and thereby to increase the capability to recognize errors and prevent fraud as the Company strives for bettering
itself from this point. We have already initiated discussions to study, assess and create everything necessary throughout
the remainder of the year to achieve effective disclosure controls and procedures, in particular in association with the recent
acquisition of ASPL and BBB. Nonetheless, this will remain a potential material weakness until such activities have been
fully integrated.
Management’s Report on Internal Control Over Financial
Reporting
.
Management is responsible for establishing
and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act,
as amended. Internal control over financial reporting refers to a process designed by, or under the supervision of, our Chief Executive/Interim
Chief Financial, and Chief Operating Officers, effected by our Board, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in connection with GAAP, including those policies and procedures that:
|
-
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
|
|
|
|
|
-
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
|
|
|
|
|
-
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.
|
Because of its inherent limitations, internal
control over financial reporting cannot provide absolute assurance of the prevention or detection of misstatements. In addition,
projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In connection with the preparation of this
Annual Report on Form 10-K/A for the year ended August 31, 2012, management, with the participation of our Chief Executive Officer/Interim
Chief Financial Officer, and Chief Operating Officer, have evaluated the effectiveness of our internal controls over financial
reporting, pursuant to Rule 13a-15 under the Exchange Act, as of August 31, 2012 in order to determine the potential for or the
existence of material weaknesses, defined as a deficiency, or a combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility a material misstatement of the company's annual or interim financial statements
will not be prevented or detected on a timely basis. Our Chief Executive, Chief Financial, and Chief Operating Officer, have concluded
the design and operation of our internal controls and procedures are not effective as of August 31, 2012.
Because of these material weaknesses, Management
has concluded the Company did not maintain effective internal control over financial reporting as of August 31, 2012, based on
the criteria established in "Internal Control-Integrated Framework" issued by the COSO, criteria set forth by the Committee
of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework. It
is the intention of the present Management to continue to study and establish COSO Control-Integrated Framework within Wholehealth
Products, Inc. during the coming year as we begin to expand our present number of personnel and activities.
There were no significant changes previously
in our internal controls over financial reporting that occurred during the fourth fiscal quarter that have materially affected,
or are reasonably likely to materially affect, our internal controls over financial reporting.
This Annual Report on Form 10-K/A does not
include an attestation report of the Company’s independent registered public accounting firm regarding internal control over
financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant
to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual
Report on Form 10-K/A.
ITEM 9B. OTHER INFORMATION
None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE.
The Company’s directors and executive
officers and their ages as of August 31, 2012 are as follows:
Name
|
Age
|
Position
|
Joseph Arcaro
|
48
|
President, Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors
|
Biographical information for Joseph Arcaro
Mr. Arcaro attended Ohio State University
to 2003 and was a stock broker with a series 7, 63 and 65 licenses-From 2004 to present Mr. Arcaro has been self employed as a
business and investment consulting to multiple publicly held companies.
Compliance With Section 16(a) of
the Exchange Act
The Company does not have a class of
securities registered pursuant to Section 12 of the Securities Exchange Act of 1934. Accordingly, the Company's executive officers
and directors and persons who own more than 10% of its equity securities are not subject to the beneficial ownership reporting
requirements of Section 16(a) of that Act. However, although not required, certain of such persons voluntarily file beneficial
ownership reports with the Securities and Exchange Commission.
Code of Ethics and Corporate Policies
Wholehealth Products, Inc. has created and
adopted a Code of Ethics and Corporate Policy. Since its inception, the policy has been updated and the current policy is
presented below:
In all societies, the opportunity to be a successful
member of the community is an important role we must all be a part of. Any company must, therefore, understand its critical
role and how to be a good member of that community. Like a three-legged stool, of which all three legs must exist in order for
it to stand, we at Wholehealth Products, Inc. see three critical components for our success and ability to be a good member of
our community at large, both here and abroad: The Company, Investors & Shareholders, and our Customers & Patients. In
no particular order do these responsibilities preside, since all are critical, required for success, and important to the Company
and our communities in which we reside, work and play.
Therefore, one of those stool legs
stands for our responsibility to the Company, including employees, near and far, in house and out, research, development, sales,
and marketing members through to our vendors. We recognize their merit and aim for all to engender a sense of well-being and security
in their jobs through good working conditions, relationships, and compensation for a job well done and helping them address and
fulfill their family responsibilities. Furthermore, there is equal opportunity for employment, development, advancement, and allowance
for suggestions to advance the Company. Lastly, we provide management and guidance, through being good leaders and enabling opportunities
for redressing issues.
Another leg of the stool stands for
the responsibility to our investors and stockholders. Although the Company must experiment with new ideas and plans, it is
tantamount to being successful, for through our success, we are able to return this to our investors and shareholders, without
whom we would not exist as a Company. We will therefore, utilize research as a means to an end, developing innovative programs
and advancing the state of the Company as a result, with the clear intention to ensure success and appreciation of those who believe
in us and in our dreams, research, plans and our provision of ultimately useful products for the community.
The final leg of the stool represents
how we must always be cognizant of those who use our products and services. In meeting their needs, everything we do should
be designed with the highest quality in mind so as to ensure a valuable end product for those for whom we ultimately work, our
customers and patients.
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth information
about all cash and non-cash compensation awarded to, earned by, or paid to (i) all persons serving as the Company’s principle
executive officer during the last two fiscal years; (ii) all persons serving as the Company’s principle financial officer
during the last two fiscal years; (iii) the Company’s three most highly compensated executive officers (other than principle
executive officers and principle financial officers) serving as such at the end of the last two fiscal years; and (iv) up to two
additional persons for whom disclosure would have been provided pursuant to clause (iii) above but for the fact that the person
was not serving as an executive officer of the Company at the end of the last fiscal year, and each current director of the Company
during fiscal years ended August 31, 2012 and 2011.
Name
|
Principal Position
|
Date
|
Salary
|
Shares of Stock Awarded
|
Stock Value
|
Total Compensation
|
None
The Company did not pay or accrue any
other compensation, in the form of bonus, stock awards, option awards, incentive plan compensation or nonqualified deferred compensation
earnings to any executive officer for services as an executive officer during the fiscal years ended August 31, 2012 and 2011;
neither were there any prerequisites or other personal benefits. The Company does not have any option plan, equity incentive plan
or retirement plan at the present time.
The Company’s Directors are compensated
for their participation on the Board of Directors for performance of their duties as directed by the Chairman of the Company. The
Board of Directors has not set a fixed compensation fee plan for Directors, but chooses to review Board and individual Director
performance on an annual basis and compensation is earned on a merit-system.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The following table sets forth, as
at August 31, 2012 certain information with respect to the beneficial ownership of the Company’s common stock by each person
known by us to be the beneficial owner of more than five percent (5%) of the Company’s common stock; by each of the Company’s
current directors and named executive officers; and by all executive officers and directors as a group
Name and Address
|
Number of Shares Beneficially Owned
(1,2)
|
Percentage of Common Stock
|
|
Joseph Arcaro
3800 Howard Hughes
Pkwy.
Las Vegas, Nevada 89169
|
100,000,000
|
65%
|
|
(1) Percentages based on 153,814,054 shares of common stock issued
and outstanding as of August 31, 2012.
|
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE
None.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The following is a summary of the fees billed
by the Company’s auditor Malone & Bailey, PC and GBH CPAs, PC for professional services rendered for each of the last
two fiscal years ended August 31, 2012 and 2011:
Service
|
|
2012
|
|
2011
|
Audit Fees
|
$
|
-
|
$
|
-
|
Audit-Related Fees
|
|
-
|
|
-
|
Tax Fees
|
|
-
|
|
-
|
All Other Fees
|
|
-
|
|
-
|
Total
|
$
|
-
|
$
|
-
|
AUDIT FEES consist of fees billed for
professional services rendered for the audit of the consolidated financial statements included in the Company’s annual reports,
reviews of the Company’s interim consolidated financial statements included in the Company’s quarterly reports, or
other services that are normally provided by the principal accountant in connection with statutory and regulatory filings or engagements,
such as financial reports filed with the Securities and Exchange Commission.
AUDIT-RELATED FEES. None.
TAX FEES consist of fees billed for
professional services for tax compliance, tax advice and tax planning, including assistance regarding compliance with federal,
state and local tax rules and regulations and consultation in connection with various transactions and acquisitions.
ALL OTHER FEES consist of fees billed
for products and services provided by the principal accountant other than Audit Fees, Audit-Related Fees and Tax Fees.
The Company does not have an Audit
Committee. The Board of Directors performs the functions that would be performed by an audit committee. The Board pre-approves
all audit and non-audit services provided by the independent auditors. These services may include audit services, audit-related
services, tax services and other services as allowed by law or regulation. Pre-approval is generally provided for up to one year
and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specifically
approved amount. The independent auditors and management are required to periodically report to the Board regarding the extent
of services provided by the independent auditors in accordance with this pre-approval and the fees incurred to date. The Board
may also pre-approve particular services on a case-by-case basis.
The Board pre-approved 100% of the
Company's 2012 and 2011 audit fees, audit-related fees, tax fees, and all other fees. To the Company's knowledge, none of the hours
expended on the principal accountant's engagement to audit the Company's financial statements for the fiscal years ended August
31, 2012 and 2011 were attributed to work performed by a person other than the principal accountant's full-time employees.
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Except as so indicated in Exhibits 32.1 and 32.2, the following
exhibits are filed as part of, or incorporated by reference, this Annual Report on Form 10-K/A.
|
|
|
Incorporated by reference
|
Exhibit
|
Exhibit Description
|
Filed herewith
|
Form
|
Period ending
|
Exhibit
|
Filing
date
|
3.1
|
Articles of Incorporation
|
|
SB-2
|
|
3.1
|
5/3/2006
|
3.2
|
Certificate of Amendment to the Articles of Incorporation
|
|
SB-2/A
|
|
3.2
|
1/31/2008
|
3.3
|
Certificate of Amendment to the Articles of Incorporation
|
|
S-8
|
|
3.3
|
3/12/2007
|
3.4
|
Bylaws of the Company
|
|
8-A
|
|
3.4
|
11/9/2006
|
4.1
|
Specimen of Stock Certificate
|
|
S-8
|
|
4.1
|
11/9/2006
|
31.1*
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|
|
|
|
31.2*
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|
|
|
|
32.1*
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|
|
|
|
32.2*
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|
|
|
|
101.INS**
|
XBRL Instance Document
|
X
|
|
|
|
|
101.SCH**
|
XBRL Taxonomy Extension Schema Document
|
X
|
|
|
|
|
101.CAL**
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
|
|
|
|
101.LAB**
|
XBRL Taxonomy Extension Label Linkbase Document
|
X
|
|
|
|
|
101.PRE**
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
X
|
|
|
|
|
101.DEF**
|
XBRL Taxonomy Extension Definition Linkbase Definition
|
X
|
|
|
|
|
*Exhibits 32.1 and 32.2 are being furnished and shall not
be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise
stated in such filing.
**
Furnished
herewith.
WHOLEHEALTH PRODUCTS, INC
|
BALANCE SHEET
|
(Audited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
August 31,
|
|
|
|
August 31,
|
|
|
|
|
2012
|
|
|
|
2011
|
|
Assets:
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
—
|
|
|
$
|
—
|
|
Accounts Receivable
|
|
|
—
|
|
|
|
—
|
|
Total Current Assets
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
$
|
—
|
|
|
$
|
—
|
|
Loan Payable - Related Party
|
|
|
—
|
|
|
|
—
|
|
Total Current Liabilities
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Equity (Deficit):
|
|
|
|
|
|
|
|
|
Preferred Stock par value $1.00 authorized 100,000,000
|
|
|
|
|
|
|
|
|
shares, Issued 0 shares respectively
|
|
|
—
|
|
|
|
—
|
|
Common Stock, par value $0.001, 1.2 billion authorized
|
|
|
|
|
|
|
|
|
shares issued and outstanding 153,814,054 and 53, 814, 054
|
|
|
153,814
|
|
|
|
53,814
|
|
Additional Paid in Capital
|
|
|
14,209,969
|
|
|
|
13,937,969
|
|
Accumulated Deficit
|
|
|
(14,363,783
|
)
|
|
|
(13,991,783
|
)
|
Total Stockholders' Deficit
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders' Deficit
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements.
WHOLEHEALTH PRODUCTS, INC.
|
STATEMENTS OF OPERATIONS
|
(Audited)
|
|
|
|
|
|
|
|
For the Years Ended
|
|
|
August 31,
|
|
August 31,
|
|
|
2012
|
|
2011
|
Revenues
|
|
$
|
—
|
|
|
$
|
—
|
|
Costs of Services
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Gross Margin
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
Stock for Services
|
|
|
360,000
|
|
|
|
—
|
|
Salaries
|
|
|
—
|
|
|
|
—
|
|
General and Administrative
|
|
|
12,000
|
|
|
|
12,000
|
|
Operating Expenses
|
|
|
372,000
|
|
|
|
12,000
|
|
|
|
|
|
|
|
|
|
|
Operating (Loss)
|
|
|
(372,000
|
)
|
|
|
(12,000
|
)
|
|
|
|
|
|
|
|
|
|
Gain (Loss) Before Taxes
|
|
|
(372,000
|
)
|
|
|
(12,000
|
)
|
|
|
|
|
|
|
|
|
|
Income Tax
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss)
|
|
$
|
(372,000
|
)
|
|
$
|
(12,000
|
)
|
|
|
|
|
|
|
|
|
|
Loss per Share, Basic &
|
|
|
|
|
|
|
|
|
Diluted
|
|
$
|
(0.01
|
)
|
|
$
|
(0.00
|
)
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares
|
|
|
|
|
|
|
|
|
Outstanding
|
|
|
62,147,338
|
|
|
|
53,814,054
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements.
WHOLEHEALTH PRODUCTS, INC.
|
(F.K.A GULF WESTERN PETROLEUM CORP.)
|
STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)
|
(Audited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
Deficit
|
|
|
|
|
|
|
|
|
Preferred
|
|
|
|
Preferred
|
|
|
|
Common
|
|
|
|
Stock
|
|
|
|
Paid in
|
|
|
|
Accumulated During
|
|
|
|
|
|
|
|
|
Shares
|
|
|
|
Stock
|
|
|
|
Shares
|
|
|
|
Amount
|
|
|
|
Capital
|
|
|
|
Development Stage
|
|
|
|
Total
|
|
Balance August 31, 2010
|
|
|
—
|
|
|
|
—
|
|
|
|
53,814,054
|
|
|
$
|
53,814
|
|
|
$
|
13,925,969
|
|
|
$
|
(13,979,783
|
)
|
|
$
|
—
|
|
Net Loss for the period
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
12,000
|
|
|
|
(12,000
|
)
|
|
|
—
|
|
Balance August 31, 2011
|
|
|
—
|
|
|
|
—
|
|
|
|
53,814,054
|
|
|
$
|
53,814
|
|
|
$
|
13,937,969
|
|
|
$
|
(13,991,783
|
)
|
|
$
|
—
|
|
Shares issued for services
|
|
|
—
|
|
|
|
—
|
|
|
|
100,000,000
|
|
|
|
100,000
|
|
|
|
260,000
|
|
|
|
—
|
|
|
|
360,000
|
|
Net loss
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
12,000
|
|
|
|
(372,000
|
)
|
|
|
(360,000
|
)
|
Balance August 31, 2012
|
|
|
—
|
|
|
|
—
|
|
|
|
153,814,054
|
|
|
$
|
153,814
|
|
|
$
|
14,209,969
|
|
|
$
|
(14,363,783
|
)
|
|
$
|
—
|
|
The accompanying notes are an integral part of these financial statements.
|
|
|
WHOLEHEALTH PRODUCTS, INC.
|
STATEMENTS OF CASH FLOWS
|
(Audited)
|
|
|
|
|
|
|
|
For the Years Ended
|
|
|
August 31,
|
|
August 31,
|
|
|
2012
|
|
2011
|
CASH FLOW FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Net Loss for the Period
|
|
$
|
(372,000
|
)
|
|
$
|
(12,000
|
)
|
Adjustments to reconcile net loss to net cash
|
|
|
|
|
|
|
|
|
used by operating activities:
|
|
|
|
|
|
|
|
|
Shares issued for Services and contributed services
|
|
|
372,000
|
|
|
|
12,000
|
|
Changes in Operating Assets and Liabilities:
|
|
|
—
|
|
|
|
—
|
|
Increase in Inventory
|
|
|
—
|
|
|
|
—
|
|
Increase in Accounts Payable
|
|
|
—
|
|
|
|
—
|
|
Net Cash (Used) in Operating Activities
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Purchase of Subsidiaries
|
|
|
—
|
|
|
|
—
|
|
Net Cash Used by Investing Activities
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Proceeds from Notes Payable - Related Parties
|
|
|
—
|
|
|
|
—
|
|
Net Cash Provided by Financing Activities
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Net (Decrease) Increase in Cash
|
|
|
—
|
|
|
|
—
|
|
Cash at Beginning of Period
|
|
|
—
|
|
|
|
—
|
|
Cash at End of Period
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
|
|
|
|
|
Cash paid during the year for:
|
|
|
|
|
|
|
|
|
Interest
|
|
$
|
0
|
|
|
$
|
0
|
|
Franchise and Income Taxes
|
|
$
|
0
|
|
|
$
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
accompanying notes are an integral part of these financial statements.
WHOLEHEALTH PRODUCTS, INC
(FORMERLY GULF WESTERN PETROLEUM INC.)
NOTES TO FINANCIAL STATEMENTS
AUGUST 31, 2012 AND 2011
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
Wholehealth Products, Inc. formerly Gulf Western
Petroleum Corporation (the Company) was incorporated on February 21, 2006 in the State of Nevada as Georgia Exploration, Inc. The
name was originally changed on March 8, 2007 and recently in July 2012 to Wholehealth Products, Inc. The Company was engaged in
the acquisition, exploration and development of oil and natural gas reserves in the United States.
The Company today is in the business of developing,
manufacturing and marketing in vitro diagnostic (IVD) tests for over-the-counter (OTC or consumer), and point-of-care (POC or professional)
use markets. The Company currently manufactures and markets a range of diagnostic test kits for consumer use through over-the-counter
(OTC) sales, and for use by health care professionals, generally located at medical clinics, physician offices and hospitals known
as Points-of-Care (POC), in the United States. These test kits are known as in vitro diagnostic test kits or “IVD”
products.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Basis of presentation
The Company’s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).The
pr
e
p
aration
of
f
i
nancial stat
e
m
ents
in
confor
m
ity
with
accounting principles
g
e
n
e
r
a
lly
accepted
in
the
United States
of
A
m
erica
r
e
quir
e
s
m
anage
m
ent
to
m
ake
est
i
m
a
tes
and
a
ssu
m
p
ti
o
n
s
t
h
at
a
ff
ect
t
h
e
r
e
p
o
rted
a
m
ounts
of assets
a
n
d
lia
b
i
lities
a
n
d
d
iscl
o
sure
o
f
c
on
tin
g
e
n
t
assets
a
n
d
lia
b
ili
t
ies
at
t
h
e
d
ate
o
f
the
f
i
n
a
n
cial
stateme
n
ts
and
t
h
e re
p
o
rt
e
d
a
m
o
u
nts
o
f
r
e
v
e
nu
e
s
a
n
d
e
x
p
e
ns
e
s
d
u
ri
n
g
t
h
e
r
ep
o
rti
n
g
p
e
ri
o
d
.
Act
u
al
r
e
s
u
lts
could
di
f
f
e
r
f
rom those est
i
m
ates.
M
anage
m
ent
f
u
r
t
her
a
ck
n
o
w
l
edg
e
s
t
h
at
it
is
solely res
po
nsible
f
o
r
ad
opti
n
g
s
o
un
d
acc
ou
nti
n
g practices,
esta
b
lis
h
ing and
m
aintaining
a
syst
e
m of
internal accounting
control
and
pr
e
v
e
n
ting
and d
e
tecting
fraud.
The
Co
m
p
any
'
s
syst
e
m of
i
n
ternal
ac
c
o
u
nti
n
g
c
o
nt
ro
l
is
design
e
d
t
o
as
s
u
r
e
,
a
m
ong oth
e
r
ite
m
s
,
t
h
at
1
)
re
c
o
r
d
ed
t
ransact
i
o
ns
are vali
d
;
2
) valid
transactions
a
re
re
c
o
rded;
and
3)
tr
an
sactions
are
r
e
c
o
r
d
ed
in
t
h
e
pro
p
er
p
er
i
o
d
in
a
t
i
mely
m
a
nn
er
to
prod
u
ce fi
n
a
n
cial
stateme
n
ts
w
h
ich
p
rese
n
t
fa
i
rly
t
h
e
fi
n
a
n
cial
c
o
n
d
iti
o
n,
res
u
lts
o
f
o
p
erati
on
s
and
cash
flows
o
f
t
h
e
Co
m
p
any for
t
h
e
respective
periods
being
presented
Use of estimates
The preparation of financial statements in
conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful
lives of property and equipment. Actual results could differ from those estimates.
Cash equivalents
The Company considers all highly liquid investments
with a maturity of three months or less when purchased to be cash equivalents.
Fair value of financial instruments
The Company follows paragraph 825-10-50-10
of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37
of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial
instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted
in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and
comparability in fair value measurements and
related disclosures, Paragraph 820-10-35-37
establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3)
broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical
assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph
820-10-35-37 are described below:
|
|
|
Level 1
|
|
Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
|
|
|
|
Level 2
|
|
Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
|
|
|
|
Level 3
|
|
Pricing inputs that are generally observable inputs and not corroborated by market data.
|
The carrying amount of the Company’s
financial assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the
short maturity of those instruments. The Company’s notes payable approximate the fair value of such instruments based upon
management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at
August 31, 2012.
The Company does not have any assets or liabilities
measured at fair value on a recurring or a non-recurring basis.
Equipment
Equipment is recorded at cost. Expenditures
for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation
of equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over
the assets estimated useful life of three (3) or seven (7) years. Upon sale or retirement of equipment, the related cost and accumulated
depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
Impairment of long-lived assets
The Company follows paragraph 360-10-05-4 of
the FASB Accounting Standards Codification for its long-lived assets. The Company’s long-lived assets, which includes computer
equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset
may not be recoverable.
The Company assesses the recoverability of
its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group
of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any,
is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the
asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined
to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book
values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.
The Company determined that there were no impairments
of long-lived assets as of August 31, 2012.
Commitments and contingencies
The Company follows subtopic 450-20 of the
FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising
from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has
been incurred and the amount of the assessment can be reasonably estimated.
Revenue recognition
The Company follows paragraph 605-10-S99-1
of the FASB Accounting Standards Codification for revenue recognition. The Company will recognize revenue when it is realized or
realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met:
(i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer,
(iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.
Income taxes
The Company follows Section 740-10-30 of the
FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future
tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax
assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using
enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced
by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the Statements of Income and Comprehensive Income in the period that includes the enactment date.
The Company adopted section 740-10-25 of the
FASB Accounting Standards Codification (“Section 740-10-25”) with regards to uncertainty income taxes. Section 740-10-25
addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the
financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if
it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical
merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on
the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section
740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim
periods and requires increased disclosures. The Company had no material adjustments to its liabilities for unrecognized income
tax benefits according to the provisions of Section 740-10-25.
Net income (loss) per common share
Net income (loss) per common share is computed
pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed
by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net
income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock
and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding
and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented.
There were no potentially dilutive shares outstanding
as of August 31, 2012.
Cash flows reporting
The Company adopted paragraph 230-10-45-24
of the FASB Accounting Standards Codification for cash flows reporting, classifies cash receipts and payments according to whether
they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or
reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB Accounting Standards Codification
to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities
by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating
cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The
Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of
the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the
reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing
and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB
Accounting Standards Codification.
Advertising Costs
The Company expenses the cost of advertising
and promotional materials when incurred. Total Advertising costs were $0 for 2012 and 2011.
Subsequent events
The Company follows the guidance in Section
855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent
events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting
Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed
to users, such as through filing them on EDGAR.
Recently issued accounting pronouncements
The following accounting standards were issued as of December
26, 2011:
ASU 2010-06, Fair Value Measurements and Disclosures (Topic
820) – Improving Disclosures about Fair Value Measurements.
This ASU affects all entities that are
required to make disclosures about recurring and nonrecurring fair value measurements under FASB ASC Topic 820, originally issued
as FASB Statement No. 157,
Fair Value Measurements
. The ASU requires certain new disclosures and clarifies two existing
disclosure requirements. The new disclosures and clarifications of existing disclosures are effective for interim and annual reporting
periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the
roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December
15, 2010, and for interim periods within those fiscal years.
ASU 2011-04,
Fair Value Measurement (Topic 820) –
Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs
This ASU supersedes most of the guidance
in Topic 820, although many of the changes are clarifications of existing guidance or wording changes to align with IFRS 13. In
addition, certain amendments in ASU 2011-04 change a particular principle or requirement for measuring fair value or disclosing
information about fair value measurements. The amendments in ASU 2011-04 are effective for public entities for interim and annual
periods beginning after December 15, 2011.
|
NOTE 3 – GOING CONCERN
As reflected in the accompanying financial
statements, the Company had an accumulated deficit of $60,813,783 at August 31, 2012.
While the Company is attempting to commence
operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s
daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that
the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the
Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in
its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going
concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.
The financial statements do not include any
adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE 4 – RELATED PARTY TRANSACTIONS
Free office Space
The Company leased space from its chief operating
officer. The Company has not recognized this cost as it was immaterial to the financial statements.
NOTE 5 – INCOME TAX
Deferred taxes are provided on a liability
method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry
forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences
between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be
realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Net deferred tax assets consist of the following
components as of August 31, 2012 and 2011:
|
|
August 31, 2012
|
|
August 31, 2011
|
Deferred Tax Assets – Non-current:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOL Carryover
|
|
$
|
(13,944,283
|
)
|
|
$
|
(13,944,283
|
)
|
|
|
|
|
|
|
|
—
|
|
Less valuation allowance
|
|
|
13,944,283
|
|
|
|
13,944,283
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets, net of valuation allowance
|
|
$
|
—
|
|
|
$
|
—
|
|
The income tax provision
differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing
operations for the period ended August 31, 2012 and 2011 due to the following:
|
|
2012
|
|
2010
|
|
|
|
|
|
Book Income
|
|
|
(372,000
|
)
|
|
|
—
|
|
Meals and Entertainment
|
|
|
—
|
|
|
|
—
|
|
Stock for Services 360,000
|
|
|
360,000
|
|
|
|
—
|
|
Accrued Payroll
|
|
|
12,000
|
|
|
|
—
|
|
Valuation allowance
|
|
|
—
|
|
|
|
—
|
|
|
|
$
|
—
|
|
|
$
|
—
|
|
At August
31, 2012, the Company had net operating loss carry forwards of approximately $13,944,283 that may be offset against future taxable
income from the year 2013 to 2033. No tax benefit has been reported in the August 31, 2012 financial statements since the potential
tax benefit is offset by a valuation allowance of the same amount.
Due to the change in ownership provisions of the Tax Reform Act
of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should
a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.
NOTE 6 - COMMON STOCK
In July 2012 the Company issued 100,000,000 shares of stock to its
officer. The shares were valued at market which at the time was .$.0036 per share. The Company has recognized the issuance under
stock for services in the statement of operations.
NOTE 7 – SUBSEQUENT EVENTS
Management has evaluated subsequent events
pursuant to the requirements of ASC Topic 855 and has determined that other than listed below, no material subsequent events exist.
|
1.
|
In September 2012 the Company effectuated a 130 to 1 reverse stock split.
|
SIGNATURES
Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
WHOLEHEALTH PRODUCTS, INC.
By:
/s/ Charles Strongo
Charles Strongo
President, Chief Executive Officer
(Principal Executive Officer On behalf of the Registrant)
Date: January 29, 2013
|
By:
/s/ Richard Johnson
Richard Johnson
Treasurer
(Principal Financial Officer)
Date: January 29, 2013
|
Wholehealth Products (CE) (USOTC:GWPC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Wholehealth Products (CE) (USOTC:GWPC)
Historical Stock Chart
From Feb 2024 to Feb 2025